The goal of this project is to address PQ7: What in vivo imaging methods can be developed to determine and record the identity, quantity, and location of each of the different cell types that contribute to the heterogeneity of a tumor and it microenvironment? Heterogeneity exists in tumor cell response to treatment, and in the pro-tumor vs. anti-tumor behavior of the cells in the microenvironment (e.g. fibroblasts, immune cells). However, there are a lack of in vivo imaging methods that can quantify this heterogeneity, thus limiting our understanding of cellular-level tumor behavior, and limiting our ability to develop improved cancer treatments. Cellular metabolism provides dynamic insight into individual cell behavior. We and others have shown that tumor cell metabolism reflects anti-cancer drug response, and tumor cells alter their metabolic activities in order to resist drug treatment. The metabolism of tumor-associated fibroblasts also support malignancy, by supplying nutrients to drive tumor growth. Additionally, the metabolism of immune cells is reflective of their pro- and anti-tumor behavior, with distinct changes in metabolic activities between M1-like and M2-like macrophages, between CD4+ and CD8+ T cells, and within the CD4+ T cell subset. Due to the key role of metabolism in maintaining the tumor and its microenvironment, drugs that disrupt the metabolism of tumor cells and cells in the microenvironment have been FDA approved for breast cancer treatment in combination with standard therapies. The goal of this proposal is to develop and validate optical metabolic imaging (OMI) to quantify dynamic metabolic heterogeneity within the tumor cell, fibroblast, macrophage, and T cell populations in tumors in vivo. Multiphoton microscopy will resolve individual cells within the Polyoma middle T (PyMT) mouse model of breast cancer throughout a treatment time-course. Autofluorescence from the metabolic co-enzymes NADH and FAD will quantify cellular metabolism, and report on metabolic heterogeneity within cell populations. Specifically, OMI will measure the optical redox ratio of each cell (fluorescence intensity of NADH divided by that of FAD), which reflects redox balance in a cell. OMI also quantifies the fluorescence lifetimes of NADH and FAD, which reflect the enzyme binding activity of these molecules. Our published work and preliminary data demonstrate that OMI is sensitive to heterogeneous drug response in tumors in vivo, and OMI can distinguish sub-types of tumor cells and immune cells. The proposed work will validate in vivo OMI of tumor heterogeneity with ex vivo flow cytometry and in vivo imaging of fluorescent cell surface markers. The proposed aims will test the hypothesis that in vivo OMI can record the identity, quantity, and location of different cell types that contribute to the metabolic heterogeneity of a tumor and its microenvironment. These tools will enable longitudinal quantification of the in vivo metabolic heterogeneity of tumor cells, fibroblasts, macrophages, and T- cells. The insights gained from these measurements can be used to develop improved cancer treatments that combat tumors on a single-cell level in order to achieve remission-free survival.

Public Health Relevance

The goal of this proposal is to develop and validate tools to quantify the metabolic heterogeneity of tumors in living animals over a time-course of treatment. The insights gained from these measurements can be used to develop improved cancer treatments that combat tumors on a single-cell level in order to achieve remission-free survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA205101-04
Application #
9749935
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Zhang, Yantian
Project Start
2016-08-01
Project End
2021-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Morgridge Institute for Research, Inc.
Department
Type
DUNS #
012420082
City
Madison
State
WI
Country
United States
Zip Code
53715
Zhan, Yonghua; Ehlerding, Emily B; Shi, Sixiang et al. (2018) Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. J Biomed Nanotechnol 14:900-909
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65
Yu, Bo; Goel, Shreya; Ni, Dalong et al. (2018) Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater 30:e1704934
Sharick, Joe T; Favreau, Peter F; Gillette, Amani A et al. (2018) Protein-bound NAD(P)H Lifetime is Sensitive to Multiple Fates of Glucose Carbon. Sci Rep 8:5456
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Ayuso, Jose M; Gillette, Amani; Lugo-CintrĂ³n, Karina et al. (2018) Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations. EBioMedicine 37:144-157
Heaster, Tiffany M; Walsh, Alex J; Zhao, Yue et al. (2018) Autofluorescence imaging identifies tumor cell-cycle status on a single-cell level. J Biophotonics 11:
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Zhang, Susu; Zhao, Yue; Heaster, Tiffany M et al. (2018) BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML. J Cell Biochem :
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150

Showing the most recent 10 out of 20 publications